FDA Accepts Bristol Myers’ Application for Injectable Opdivo (NYSE:BMY)

Bristol Myers Squibb Building in San Diego, CA, USA.


The FDA accepted Bristol-Myers (NYSE: BMY) biologics license application for a subcutaneous formulation of its oncology drug Opdivo, also known as nivolumab, with a target action date of February 28.

The subcutaneous version is formulated with Halozyme (NASDAQ:HALO) owner

Related Articles

Back to top button